# Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

> **NCT03363373** · PHASE2 · RECRUITING · sponsor: **Y-mAbs Therapeutics** · enrollment: 122 (estimated)

## Conditions studied

- Neuroblastoma

## Interventions

- **BIOLOGICAL:** GM-CSF + Naxitamab

## Key facts

- **NCT ID:** NCT03363373
- **Lead sponsor:** Y-mAbs Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-04-03
- **Primary completion:** 2026-04
- **Final completion:** 2028-04
- **Target enrollment:** 122 (ESTIMATED)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03363373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03363373, "Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT03363373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*